For patients with confirmed PA, the differentiation of UPA from BPA is essential because surgical treatment is recommended for UPA while an oral mineralocorticoid receptor antagonist, such as spironolactone, is the first line of treatment for BPA. Here, NR3C2 is linked to urokinase-type plasminogen activator measurement.